Breaking News on Global Pharmaceutical Technology & Manufacturing

Dow obtains new oligonucleotides contact

31-Mar-2003

Related topics: Excipients, raw materials and intermediates, APIs (active pharmaceutical ingredients), Regulatory & Safety

Dow Chemical has agreed for Dowpharma, Dow's pharmaceutical manufacturing services business unit, to supply select, proprietary oligonucleotides to Montreal, Canada-based Topigen Pharmaceuticals for use in its pharmaceutical development programme.

Topigen's pharmaceutical development programme - based primarily on a synergistic blend of antisense oligonucleotides - is directed toward the treatment of a range of inflammatory respiratory diseases and is predicated on engaging multiple genes.

 

Dowpharma will supply the Canadian firm with oligonucleotides as its antisense-based products move through the phases of clinical trials to commercial production. Dowpharma is currently providing clients with both laboratory, and mid-scale, cGMP oligonucleotide development and manufacturing capabilities. A commercial unit, with an annual capacity of around 500kg, will be on-line later in 2003, the company said.

 

Copyright - Unless otherwise stated all contents of this web site are © 2012 - William Reed Business Media SAS - All Rights Reserved - For permission to reproduce any contents of this web site, please email our Syndication department copyright@wrbm.com - Full details for the use of materials on this site can be found in the Terms & Conditions

© 2012 - William Reed Business Media SAS - All rights reserved.